In addition, the type of the initiating lesion (e.g., TET2, DNMT3A, JAK2 mutations, etc.), clonal burden, and the clinical phenotype of CHIP–derived neoplasms may further confound the prognostic assessment. This evidence concerns the gene STUB1 and neoplasm.